Adagene Inc. American Depositary Shares

Adagene has signed a licensing agreement with Third Arc Bio to utilize its SAFEbody technology platform for developing two masked CD3 T cell engagers targeting unique tumor-associated antigens. The deal includes an upfront payment of $5 million and potential milestone payments up to $840 million.

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Charge Enterprises, Inc. (NA...

Here is how Boston Scientific (BSX) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.